The optimum therapy for cryptococcal meningitis in patients with the acquired
immunodeficiency syndrome (AIDS) remains unresolved. Traditional therapy consists of …

The optimum regimen for the treatment of cryptococcal meningitis in patients with AIDS is
still not totally clear. The triazoles fluconazole and itraconazole are associated with …

Abstract Treatment of cryptococcal meningitis in patients with AIDS with amphotericin B plus
flucytosine is associated with a failure rate of 20%–30%. In the absence of chronic …

Infections caused by Cryptococcus neoformans cause significant morbidity and high
mortality, particularly among immunocompromised patients. Cryptococcal meningitis is an …

We retrospectively analyzed clinical outcome of meningeal and extrameningeal
cryptococcosis in HIV-negative patients treated with amphotericin B (43 patients) or …

Background. Intravenous amphotericin B, with or without flucytosine, is usually standard
therapy for cryptococcal meningitis in patients with the acquired immunodeficiency …

Previously a rare diagnosis, cryptococcal meningitis has emerged as the most common
fungal meningitis in the US because of the AIDS epidemic. Due to the profound and …

In this clinical trial, oral fluconazole was used to treat cryptococcal meningitis in 32 patients
with Acquired Immune Deficiency Syndrome (AIDS). In 11 patients who received 200 to 400 …

Abstract Treatment of cryptococcal meningitis with amphotericin B or fluconazole is often
unsuccessful; in only 35%–40% of cases do CSF cultures become negative by 10 weeks …

Objective: We conducted a comparison of itraconazole versus amphotericin B plus
flucytosine in the initial treatment of cryptococcal meningitis in patients with AIDS and …